House investigation finds FDA, drug firm Biogen ignored internal concerns for Alzheimer’s drug

A congressional investigation into the Food and Drug Administration’s review process for an Alzheimer’s treatment found that the agency “deviated” from its standard procedures to approve the Aduhelm drug with inconsistent data.

Aduhelm is notable for being the first drug in recent years approved to treat the underlying cause of Alzheimer’s, a disease with no known cure that is characterized by progressive dementia that affects more than six million Americans, according to the Alzheimer’s Association.

The joint 18-month investigation between the House’s Oversight and Reform Committee and Energy and Commerce Committee, released on Thursday, criticizes the FDA for “atypical collaboration and interactions” with Biogen, the drug’s manufacturer.

In statements, Biogen and the FDA both said their interactions prior to Aduhelm’s green light were appropriate in the context of the approval process.

“One of my top priorities as Chair of the Committee on Oversight and Reform is ensuring that the American people have access to effective and affordable medications,” Rep. Carolyn Maloney, D-N.Y., chairwoman of the House Oversight and Reform Committee, said in a statement.

The FDA “remains committed to the integrity of our drug approval process, which includes ensuring that safe and effective new treatment options are available to the millions of people with Alzheimer’s disease living in the U.S.,” the agency said in a statement to ABC News.

“The FDA’s decision to approve Aduhelm was based on our scientific evaluation of the data contained in the application, which is described in the approval materials. … That said, the agency has already started implementing changes consistent with the Committee’s recommendations,” the statement said, in part.

The report also blasts Biogen for “an unjustifiably high price for Aduhelm” that it says was meant “to make history.” One year of the Aduhelm treatment originally cost $56,000 for a person of average weight, the report says.

“Biogen stands by the integrity of the actions we have taken,” the company said in a statement to ABC News. “As stated in the congressional report, an FDA review concluded that, ‘There is no evidence that these interactions with the sponsor in advance of filing were anything but appropriate in this situation.'”

“Alzheimer’s is a highly complex disease and we have learned from the development and launch of Aduhelm. That process is continuing to inform our work as Biogen introduces new innovative treatments to the market,” the statement read, in part.

PHOTO: A sign for the Food And Drug Administration is seen outside of the headquarters, July 20, 2020, in White Oak, Md.

A sign for the Food And Drug Administration is seen outside of the headquarters, July 20, 2020, in White Oak, Md.

Sarah Silbiger/Getty Images

Aduhelm was considered for FDA approval under the agency’s traditional pathway before the agency switched to consider the drug under its Accelerated Approval Program, according to the report.

The change in course — which the congressional investigation says occurred “abruptly” — came after the FDA internally found Aduhelm lacked “demonstrated clinical benefit necessary for traditional approval,” House investigators found.

Under the accelerated program, the FDA can approve some drugs that meet both “an unmet medical need” and “treat serious conditions,” according to the agency’s website. Aduhelm is not the only drug to be approved under this pathway, which the FDA carved out specifically to give more options to patients with diseases for which virtually no treatments exist. Accelerated approval is typically contingent upon the pharmaceutical company completing larger, longer-term studies.

PHOTO: A sign marks a Biogen facility in Cambridge, Mass., March 9, 2020.

A sign marks a Biogen facility in Cambridge, Mass., March 9, 2020.

Brian Snyder/Reuters, FILE

During the monthslong approval process, the FDA and Biogen collaborated closely. FDA and Biogen officials met, spoke or otherwise had substantial email exchanges at least 115 times, according to the congressional investigation.

Although it is typical for drug companies to work closely with the FDA during the approval process, such collaboration between Biogen and its federal regulators “exceeded the norm in some respects,” according to the FDA’s own internal review, the report says.

The cooperation came after an independent review of Aduhelm’s effects on people with Alzheimer’s cast doubt on its ability “to effectively slow cognitive and functional impairment” in patients.

And when the FDA initially approved the drug for all Alzheimer’s patients, the congressional investigation found that the move concerned some Biogen advisers who were wary of such broad approval. The advisers did not communicate such reservations to regulators, the report says.

The FDA later walked back its broad approval of the drug, eventually recommending the drug’s use in only a narrower subset of patients with early-stage disease, which more closely mirrored the group included in Aduhelm’s clinical trials.

Following the FDA’s accelerated approval of Aduhelm, the Centers for Medicare & Medicaid Services established that Medicare would only pay for the drug under limited circumstances in which patients are part of approved studies.

That move severely limits the availability and practical implications of Aduhelm, essentially making it available only to people who can pay out of pocket for treatment.

And as part of the stipulations associated with accelerated approval, Biogen has more than six years to complete the final trial, per the report. Aduhelm remains available in the meantime.

Thursday’s report comes as the FDA evaluates two additional Alzheimer’s-related drugs, with a green light from the agency possible in the coming months. Biogen helped develop one of those drugs.

“FDA must take swift action to ensure that its processes for reviewing future Alzheimer’s disease treatments do not lead to the same doubts about the integrity of FDA’s review,” the congressional report says.

Source ABC

A tech blog author and superhero who writes about technology and its impact on society, business, and everyday life

Related Posts

Elie Saab’s spring couture in Paris dreams of Thai escape

PARIS — Elie Saab whisked his guests away to Thailand for a Paris Fashion Week couture show Wednesday that gleamed with gold and intricate silk embroidery. Sheer diaphanous cloth floated…

Read more

Lloyd Morrisett, who helped launch ‘Sesame Street,’ dies

NEW YORK — Lloyd Morrisett, the co-creator of the beloved children’s education TV series “Sesame Street,” which uses empathy and fuzzy monsters like Abby Cadabby, Elmo and Cookie Monster to…

Read more

Why do so many older adults choose Medicare Advantage?

In 2022, 48% of Medicare beneficiaries were enrolled in Medicare Advantage plans instead of original Medicare, and experts predict that number will be higher in 2023. Medicare Advantage plans are…

Read more

North Carolina doctor sues over abortion pill access, in test case of federal power

In a lawsuit that could impact abortion access nationwide, a North Carolina doctor on Wednesday asked a federal district court to strike down the state’s restrictions on the abortion drug…

Read more

Edmunds: The pros and cons of software running your car

Software was a big theme for automakers attending CES 2023 in January. BMW, Stellantis, Volkswagen and a joint venture between Honda and Sony showed off upcoming or concept vehicles that…

Read more

Jill Biden’s inaugural wear to go on display at Smithsonian

WASHINGTON — First ladies typically donate their inaugural ball gowns to the Smithsonian Institution for its collection. Jill Biden is giving up two clothing ensembles, and neither one includes a…

Read more

Leave a Reply

Your email address will not be published. Required fields are marked *